StockData

Johnson & Johnson vs Dr Reddys Laboratories

JNJ and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JNJ and RDY compare

Johnson & Johnson grew revenue faster over the last twelve months (7.8% versus 3.2% for Dr Reddys Laboratories).

Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 12.8% at Dr Reddys Laboratories.

Johnson & Johnson pays a dividend yielding 1.9%; Dr Reddys Laboratories does not pay one.

Johnson & Johnson scores higher on the StockData Score (12 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJNJRDY
Size and price
Market cap$671B–
Share price$278.70$14.79
Change, 1 year42.2%6.1%
Change, 5 years75.1%17.4%
Beta (5Y)−0.30−0.32
Employees138K–
StockData Score
Total score12 (better)7
Valuation score00
Growth score3 (better)1
Performance score4 (better)2
Health score34 (better)
Dividend score2 (better)0
Valuation
P/E42.3×–
P/S6.8×–
P/B8.2×–
EV/EBITDA26.0×–
P/FCF32.6×–
PEG2.36–
FCF yield3.1%–
Fair value$150.10–
Margin of safety−85.7%–
Growth
Revenue growth (TTM)7.8% (better)3.2%
Revenue growth, 5Y average2.7%12.1% (better)
Net income growth (TTM)−35.9%−24.2% (better)
EPS growth (TTM)−36.4%−24.1% (better)
EPS growth, 5Y average14.9%19.9% (better)
Profitability
Gross margin67.6% (better)52.8%
Operating margin–15.0%
Net margin16.2% (better)12.8%
FCF margin20.7% (better)10.0%
Return on equity20.0% (better)12.1%
Return on invested capital–9.7%
Financial health
Debt / equity0.550.21 (better)
Net debt / EBITDA1.020.87 (better)
Interest coverage–13.5×
Current ratio1.021.80 (better)
Altman Z-score5.18–
Piotroski F-score44
Dividends and buybacks
Dividend yield1.9%–
Payout ratio–15.5%
Years of dividend growth16 (better)0
Dividend growth, 5Y average5.2%9.9% (better)
Buyback yield1.2%–
Shareholder yield3.1%–
Ownership
Held by institutions74.8%15.1%
Held by insiders0.04%13.6%
Insider net buying, 12 months−$154M–
Superinvestors holding6–
Short interest, % of float0.71%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.